Boehringer Ingelheim and Connexios Life Sciences Enter Agreement for AMPK Activators

May 09, 2014

Boehringer Ingelheim and Connexios Life Sciences, a Bangalore based biotechnology company, reported an exclusive global research collaboration agreement for AMPK agonists for the treatment of patients with Type 2 Diabetes.

As part of the agreement, Boehringer Ingelheim obtains global rights to CNX-012, Connexios Life Sciences’ program on AMPK activators. The program includes CNX-570 and other compounds in early pre-clinical development. Boehringer Ingelheim will be responsible for all further development and commercialization of the candidates from the AMPK program. Further terms and financial details were not disclosed.

Source: Boehringer Ingelheim

lorem ipsum